- BioNTech is committed to
contributing to the UN Sustainable Development Goals (SDGs),
particularly the promotion of good health and well-being for all
people of all ages
- The Company has signed the UN
Global Compact and is committed to good corporate governance, the
exercise of social and societal responsibility and the mitigation
of human impact on the world’s climate and environment
- BioNTech’s efforts have been
recognized by the rating agency ISS ESG, part of the Institutional
Shareholder Services group (ISS), which awarded the Company a
“Prime” ESG (ESG; Environmental, Social, Governance) rating (top
10% in the industry) following publication of its first
sustainability report for 2020
- The Company aims to become climate
neutral by 2030; 85% of its total energy consumption is covered by
renewable electricity, climate neutral natural gas and climate
neutral district heating
- BioNTech is committed to diversity;
its employees represent more than 60 nationalities and females
account for 45% of top manager positions
MAINZ, Germany, May 21, 2021
– BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a
next generation immunotherapy company pioneering novel therapies
for cancer and infectious diseases, has published its first
Sustainability Report. The report focuses on the Company’s
commitment to making an impact on good health and well-being,
anchoring responsibility in its core business, ensuring BioNTech’s
resilience through responsible governance, creating values and
shaping a sustainable corporate culture for growth. BioNTech was
awarded a "Prime" rating in its first ESG rating by the rating
agency ISS ESG. BioNTech is now ranked by ISS ESG in the top 10% of
all rated companies in the Pharmaceuticals and Biotechnology
sector.
“BioNTech was founded in 2008 with the vision of
improving the health of people worldwide by harnessing the full
potential of the immune system. This is what still drives us every
day”, said Dr. Sierk Poetting, CFO and COO of
BioNTech. “The publication of our first Sustainability
Report is a milestone for us, showcasing not only the contribution
we aspire to make to society through our innovative research, but
also the wider responsibility we take on as a company. The ‘Prime’
rating from ISS ESG is a significant independent recognition of our
sustainability performance. As a signatory of the UN Global
Compact, we will also continue to execute our key responsibilities
and provide regular updates on our activities, efforts and progress
to this end.”
Responsibility in the core business: having
an impact on good health and well-beingBioNTech’s mission and
its core business model is to develop novel therapies for cancer,
infectious and other serious diseases in order to help improve the
health of people worldwide. With this commitment, BioNTech
contributes to the United Nations Sustainable Development Goals
(SDGs) – especially to the third SDG: the promotion of good health
and well-being for all people of all ages. Particularly during the
COVID-19 pandemic, the vital importance of the latter has become
apparent.
With its proprietary technology and decade-long
experience in mRNA research, BioNTech successfully developed a
well-tolerated and effective vaccine against COVID-19 in only ten
months – the first COVID-19 vaccine approved after a Phase 3 trial
and the first mRNA-based vaccine for use in humans worldwide. Thus,
BioNTech is making a significant contribution to address the
pandemic, thereby saving lives and securing livelihoods.
To fulfill its mission of improving the health
of people worldwide, BioNTech has become a global, fully integrated
immunotherapy company. This includes addressing global health
challenges such as COVID-19. In addition to its vaccine against
COVID-19, the Company is developing vaccine candidates against nine
other infectious diseases, such as HIV and Tuberculosis, both of
which disproportionately affect people living in lower and
lower-middle income countries. BioNTech is also working on
mRNA-based vaccines and therapies to address other public health
challenges, such as autoimmune disease.
In addition, BioNTech is advancing its
diversified immuno-oncology pipeline across four drug classes: mRNA
therapeutics, cell therapies, next-generation antibodies, and small
molecule immunomodulators. The Company currently has 14 product
candidates in 15 ongoing clinical trials. BioNTech is focused on
accelerating the path-to-market for its lead oncology programs to
make them available to cancer patients as quickly as possible.
Responsible governanceThe Company pursues
the objective of sustainable value creation by addressing the
interests of its shareholders, workforce and other stakeholders.
The Sustainability Report describes its compliance and ethics
principles, as well as its approach to human rights in the supply
chain.
An important element of the report is the
description of how patient safety is ensured in all phases of the
product life cycle: from clinical development to the authorized and
marketed product, as well as maintaining the highest quality
standards in manufacturing, product labeling, and the disclosure of
product-related risks and benefits. In September 2020, BioNTech’s
Chief Executive Officer (CEO) and co-founder Ugur Sahin, together
with eight other bio-pharma CEOs, pledged to continue to make the
safety and well-being of vaccinated individuals the top priority in
the development of the first COVID-19 vaccines. This does not only
apply to the vaccine candidates developed to address COVID-19, but
to all product candidates BioNTech is developing.
Responsibility for protecting the environment
and climateBioNTech supports the legally binding international
treaty on climate change (“Paris Agreement”). The Company intends
to be climate neutral by 2030 at the latest, despite continuing to
grow and whilst maintaining the highest standards of quality in
research and development and commercial production.
BioNTech announced a Global Climate Protection
Strategy and will outline concrete emissions targets and KPIs as
well as tangible measures in 2021. In January 2021, BioNTech began
switching over those energy contracts which it has direct
contractual control over to agreements supplying solely renewable
electricity and climate neutral natural gas. Since January 2021,
85% of its total energy consumption (based on total energy
consumption in 2020) is already covered by energy sources that have
a climate-neutral effect for BioNTech – either directly or, with
regards to natural gas, through CO2e emission offsets implemented
by the energy provider.
Responsibility for a corporate culture of
diversityDiversity is a key aspect of the corporate culture at
BioNTech. The Company has employees from more than 60
nationalities. Women account for 54% of the total workforce and 45%
of top management below the management board. BioNTech’s track
record has proven that different cultures and perspectives enrich
the Company and are an important factor in its success. To further
promote diversity across society, BioNTech has been a signatory to
the Diversity Charter “Charta der Vielfalt” since November
2018.
About BioNTech’s first Sustainability
ReportBioNTech has been strategically addressing its corporate
responsibility since late 2019. The Company’s sustainability
reporting is guided by the standards of the Global Reporting
Initiative (GRI). The report has been prepared in accordance with
the GRI Standards: Core option. In the GRI Content Index,
references to the Sustainability Accounting Standards Board’s
(SASB) industry standards, the ten Principles of the UN Global
Compact and the Sustainable Development Goals (SDGs) are made. The
German translation of the Sustainability Report 2020 will be
available in June 2021.
The full Sustainability Report 2020 can be found
under the following link.
About BioNTechBiopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
checkpoint immuno-modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit
www.BioNTech.de
Forward-Looking Statements
This press release contains “forward-looking
statements” of BioNTech within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements may include, but may not be limited to, statements
concerning: BioNTech’s efforts to combat COVID-19; the
collaboration between BioNTech and Pfizer to develop a COVID-19
vaccine (including a potential second booster dose of BNT162b2
and/or a potential booster dose of a variation of BNT162b2 having a
modified mRNA sequence); the initiation, timing, progress, and
results of BioNTech’s research and development programs and its
current and future preclinical studies and clinical trials,
including statements regarding the timing of initiation and
completion of studies or trials and related preparatory work, the
period during which the results of the trials will become available
and BioNTech’s research and development programs; the timing of and
BioNTech’s ability to obtain and maintain regulatory approval for
its product candidates; BioNTech’s ability to identify research
opportunities and discover and develop investigational medicines;
BioNTech’s plans and targets for energy use and consumption,
including its carbon neutrality plans; and the demographic makeup
of BioNTech’s employees. Any forward-looking statements in this
press release are based on BioNTech’s current expectations and
beliefs of future events. The forward-looking statements in this
press release are neither promises nor guarantees, and you should
not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond BioNTech’s control, and
which could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to: the
ability to meet the pre-defined endpoints in clinical trials; the
ability to effectively scale our productions capabilities; and
other potential difficulties.
For a discussion of these and other risks and
uncertainties, see BioNTech’s Annual Report as Form 20-F for the
Year Ended December 31, 2020, filed with the SEC on March 30, 2021,
which is available on the SEC’s website at www.sec.gov. All
information in this press release is as of the date of the release,
and BioNTech undertakes no duty to update this information unless
required by law.
Media RelationsJasmina Alatovic +49 (0)6131 9084 1513
Media@biontech.de
Investor RelationsSylke Maas, Ph.D.+49 (0)6131 9084
0Investors@biontech.de
BioNTech (NASDAQ:BNTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
BioNTech (NASDAQ:BNTX)
Gráfica de Acción Histórica
De May 2023 a May 2024